Analysis identifies a high prevalence of pre-CAF cells in breast tissue of BRCA1/2 mutation carriers, suggesting altered epithelial and stromal interactions in cancer initiation.
Germline mutations in BRCA-1 and BRCA-2 significantly increase breast cancer risk. However, the mechanisms driving early tumorigenesis remain incompletely understood. While previous studies have primarily focused on luminal progenitors as tumor-initiating cells in BRCA-1 mut/+and BRCA-2 mut/+carriers, the impact of these mutations on the stromal microenvironment and their role in cancer initiation has notbeen thoroughly explored. We analyzed preneoplastic breast tissues from healthy BRCA-1 mut/+and BRCA-2 mut/+carriers, focusing on expression patterns and alterations of Podoplanin (PDPN), CD10, and programmed cell death ligand 2 (PD-L2) across both epithelial and stromal compartments. Our findings reveal a high prevalence of pre-CAF (PDPNhigh/CD10+) cells in the stroma of BRCA-1mut/+carriers and, for the first time, also in BRCA-2mut/+carriers. These pre-CAFs exhibited overexpression of PDPN, CD10, and PD-L2, supporting their role in early stromal remodeling. Additionally, we identified altered PD-L2 expression across stromal, basal, and luminal progenitor compartments, with distinct localization patterns in BRCA-1mut/+and BRCA-2mut/+ tissues. Our results suggest a potential mechanism through which BRCA1/2 mutations contribute to tumor initiation through early reprogramming of both stromal and epithelial compartments. These findings highlight the pivotal role of the stromal microenvironment in BRCA1/2-associated breast cancer initiation and underscore the importance of simultaneously investigating epithelial and stromal alterations in cancer risk assessment.
No takes yet. Share an insight, caveat, or question.
Leonardis et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: